Latest Merrimack Pharmaceuticals Inc. Stories

2011-08-09 00:00:28

Enrollment in Phase 1 Study of MM-302 in HER2 Positive Breast Cancer Patients Initiated by Merrimack Pharmaceuticals Cambridge, MA (PRWEB) August 08, 2011 Merrimack Pharmaceuticals, Inc.

2011-08-01 15:00:00

CAMBRIDGE, Mass., Aug. 1, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted MM-398 orphan drug status for the treatment of pancreatic cancer.

2011-06-30 11:12:00

CAMBRIDGE, Mass., June 30, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.

2011-05-11 00:00:27

Reuniting the worldwide rights allows for a broad, global development program for MM-398 (PRWEB) May 09, 2011 Merrimack Pharmaceuticals, Inc. and PharmaEngine, Inc.

2011-05-09 04:12:00

TAIPEI, May 9, 2011 /PRNewswire-Asia/ -- PharmaEngine, Inc. and Merrimack Pharmaceuticals, Inc.

2011-04-05 10:08:00

CAMBRIDGE, Mass., April 5, 2011 /PRNewswire/ -- Merrimack Pharmaceuticals, Inc.

2011-04-02 00:00:28

MM-111 in pre-clinical combinations with lapatinib and endocrine therapies MM-302 in pre-clinical studies explaining its mechanism of action Cambridge, Mass. (Vocus/PRWEB) April 01, 2011 Merrimack Pharmaceuticals, Inc.

2011-03-31 00:00:29

Robert Mulroy, President and Chief Executive Officer, will provide a company overview at Needham & Company’s 10th Annual Healthcare Conference. Cambridge, MA (Vocus/PRWEB) March 30, 2011 Merrimack Pharmaceuticals today announced that it will present at Needham & Company’s 10th Annual Healthcare Conference in New York City, New York.

Word of the Day
  • Withering but not falling off, as a blossom that persists on a twig after flowering.
The word 'marcescent' comes from a Latin word meaning 'to wither'.